GRI Bio reports Q2 net loss of $8.9M, cash $4.8M, Phase 2a IPF study on track for H2 2023

GRI Bio, Inc.

2023-Q2 EPS reported -$5.23

Net loss of $8.9M for six months ended June 30, 2023, primarily from increased R&D and G&A expenses.
Cash and equivalents $4.8M at June 30, 2023; merger with Vallon Pharmaceuticals closed.
R&D expenses Q2 2023: $0.9M (up from $0.1M); G&A $5.1M (up from $0.1M) due to merger costs.
Phase 2a biomarker study for GRI-0621 in IPF on track to launch in H2 2023.
IND-enabling studies for GRI-0803 in SLE ongoing; IND filing expected in H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

GRI Bio, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2023, and provided a business update.

View on SEC.gov

Browse all earnings releases →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-23-000145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.